Quincy Bioscience’s Prevagen Supplement
October 2020: TINA.org filed an amicus curiae brief opposing the terms of the proposed settlement agreement as unfair to consumers. To read the brief or learn about the issues raised by TINA.org, click here.
July 2020: A federal judge preliminarily approved the settlement agreement. A final fairness hearing is scheduled for November 17, 2020.
June 2020: Plaintiffs moved for preliminary approval of a settlement agreement that would provide class members with a 30 percent cash refund of the company’s suggested retail price for Prevagen products. Class members with proof of purchase may receive a maximum award of $70 while class members without proof of purchase may receive a maximum award of $12. The company also agreed to stop marketing that Prevagen improves memory without adequate scientific evidence to support such claims or qualifying the advertising claim with a disclaimer. This settlement would resolve seven lawsuits: Collins, Engert, Karanthos, Racies, Spath, and Vanderwerff, as well as one state case Miloro v. Quincy Bioscience.
April 2019: The Spath case was transferred to a court in New York. (Case No. 19-cv-3521, S.D.N.Y.)
August 2018: A class-action lawsuit was filed against Quincy Bioscience for allegedly falsely marketing the supplement Prevagen as being clinically tested to improve memory within 90 days and support “healthy brain function, sharper mind, and clearer thinking” when, according to plaintiffs, the supplement has not been clinically tested and does not provide the advertised brain and memory benefits. (Spath et al v. Quincy Bioscience Holding Company, Inc. et al, Case No. 18-cv-12416, D.N.J.)
For more of TINA.org’s coverage of Prevagen, click here.